Bio-Techne and Luminary Therapeutics sign license agreement for use of Bio-Techne’s TcBuster™ for the development of Luminary’s CAR-T cell therapies
Minneapolis, MN USA Feb 23 2021 – Bio-Techne Corporate (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufacturing of gene-modified cell therapies.